恩華藥業(002262.SZ):恩華和信獲得TEVA安泰坦於中國大陸的獨家商業化權益
格隆匯2月26日丨恩華藥業(002262.SZ)公佈,2024年2月22日,公司全資子公司恩華和信與TEVA在江蘇省徐州市經濟技術開發區龍湖西路31號恩華科技大廈簽訂了安泰坦產品獨家商業化許可和合作協議,協議期限自2024年2月22日至2029年2月22日。恩華和信獲得TEVA安泰坦於中國大陸(以下簡稱"許可區域")的獨家商業化權益。
根據獨家商業化許可和合作協議,恩華和信將獲得TEVA的安泰坦在中國大陸的獨家商業化權益。恩華和信將TEVA授權的安泰坦產品在許可區域內進行進口、經銷、推廣及銷售活動。作為對TEVA或其關聯方根據合作協議所授予的權利和許可的對價,恩華和信應向TEVA或其關聯方支付3,000萬美元的許可費,該許可費均由恩華和信以自有或自籌資金支付。
本次交易涉及的安泰坦系美國食品藥品監督管理局(FDA)2017年批准的囊泡單胺轉運蛋白2(VMAT2)抑制劑,於2020年獲得中國國家藥品監督管理局批准,用於治療成人與亨廷頓病(HD)有關的舞蹈病及遲發性運動障礙(TD),並於當年通過國家醫保談判進入醫保目錄。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.